149 results on '"Patsenker, Eleonora"'
Search Results
2. 4-O′-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice
3. Targeting senescent cholangiocytes and activated fibroblasts with B‐cell lymphoma‐extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/−) mice
4. K+-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells
5. Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites
6. Loss of hepatic Mboat7 leads to liver fibrosis
7. New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4
8. Cannabinoid Receptor Type I Modulates Alcohol-Induced Liver Fibrosis
9. Evaluation of the transforming growth factor β1 codon 25 (Arg → Pro) polymorphism in alcoholic liver disease
10. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis
11. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: Link with oxidative stress
12. Metabolic signature of electrosurgical liver dissection: 279
13. A New Model of Interactive Effects of Alcohol and High-Fat Diet on Hepatic Fibrosis
14. Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways
15. Loss of hepatic Mboat7 leads to liver fibrosis
16. Pharmacological inhibition of integrin αvβ3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis#
17. Mdr2 ( Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes
18. Herbal hepatotoxicity
19. New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4.
20. No Role of Matrixmetalloproteinase-3 Genetic Promoter Polymorphism 1171 as a Risk Factor for Cirrhosis in Alcoholic Liver Disease
21. Mo1991 - Pharmacologic Inhibition of Integrin ανβ6 Causes Tumor Shrinkage in the DSS/AOM Mouse Colon Tumor Model
22. Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model
23. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/−) mice
24. S06-4CANNABINOID SYSTEM MODULATION IN ALCOHOL-INDUCED LIVER INJURY
25. Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model
26. Cannabinoids in liver diseases
27. Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro
28. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout ( Mdr2−/−) mice.
29. Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro
30. Elevated Levels of Endocannabinoids in Chronic Hepatitis C May Modulate Cellular Immune Response and Hepatic Stellate Cell Activation
31. K+ -channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells
32. Elevated Liver Regeneration in Response to Pharmacological Reduction of Elevated Portal Venous Pressure by Terlipressin After Partial Hepatectomy
33. Metabolomic tissue signature in human non‐alcoholic fatty liver disease identifies protective candidate metabolites
34. Metabolic Signature of Electrosurgical Liver Dissection
35. Role of integrins in fibrosing liver diseases
36. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
37. M1737 Acetaldehyde May Induce Hepatic Fibrosis via the Expression of Cannabinoid Receptor
38. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease
39. Severe hepatotoxicity following ingestion of Herbalife® nutritional supplements contaminated with Bacillus subtilis
40. Inhibition of Integrin αvβ6 on Cholangiocytes Blocks Transforming Growth Factor-β Activation and Retards Biliary Fibrosis Progression
41. Evaluation of the transforming growth factor β1 codon 25 (Arg→Pro) polymorphism in alcoholic liver disease
42. Integrin αvβ6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies
43. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro
44. K+-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
45. Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites.
46. Halofuginone Induces Matrix Metalloproteinases in Rat Hepatic Stellate Cells via Activation of p38 and NFκB
47. VEGF induces proliferation, migration, and TGF-β1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase
48. Hepatotoxicity of alcohol‐induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential
49. Mycofenolate mofetil downregulates TGFβ and procollagen α1(I) and (III) mRNA expression in hepatic stellate cells
50. Halofuginone inhibits in vitro migration and proliferation of activated hepatic stellate cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.